

Restriction map and multiple cloning site (MCS) of pRevTRE Vector. All restriction sites shown are unique.

3320

Sal I

3330

ACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGTTAACATCGATAAAA

3340

Sph | Hind | Hpa |

3350

Description:

3300

3310

BamH I

pRevTRE is a retroviral Tet response vector that expresses a gene of interest from the Tetresponse element (TRE). This vector is derived from pLNCX, a retroviral vector created using elements of Moloney murine leukemia virus (MoMuLV) and Moloney murine sarcoma virus (MoMuSV) as described (1). The TRE contains seven direct repeats of the tetO operator sequence, upstream of a minimal CMV promoter, which can be bound by the tTA and rtTA transactivators. The 5' viral LTR controls expression of the transcript that contains Ψ^+ (the extended viral packaging signal) and the hygromycin resistance (Hyg') gene for antibiotic selection in mammalian cells. The TRE is derived from vectors described previously (2, 3). pRevTRE also includes the $E.\ coli\ Amp^r$ gene for antibiotic selection in bacteria.

The complete RevTet-Off and RevTet-On Systems also include the control vector pRevTRE-Luc, which was constructed by cloning the firefly luciferase gene into the *Hind* III/*Cla* I sites in the MCS of pRevTRE.



United States/Canada 800.662.2566 Asia Pacific

+1.650.919.7300

+1.650.919.7300 **Europe**

+33.(0)1.3904.6880

Japan

+81.(0)77.543.6116

Clontech Laboratories, Inc. ATakara Bio Company 1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

(PR7Y2391; published 8 November 2007)

pRevTRE Vector Information

Use:

pRevTRE can be used to establish inducible Tet Systems via retrovirus-mediated gene transfer (4). Retroviral gene transfer allows the highly efficient transduction of virtually all dividing cell types. The RevTet™ Systems are also suitable for establishing transgenic animals. In combination with the pRevTet-On or pRevTet-Off regulatory vector, a gene of interest can be inducibly expressed at high levels in response to varying concentrations of tetracycline (Tc) orTc derivatives such as doxycycline (Dox). tTA and rtTA bind to the Tetresponse element (TRE) and activate transcription from the minimal promoter in the absence or presence of Dox, respectively. pRevTRE lacks the viral genes *gag*, *pol*, and *env*, which are supplied by the packaging cell line. It can be transfected into a high titer packaging cell line and thereby mediate production of infectious, replication-incompetent retroviral particles (1, 6–7). The transcript produced by the pRevTRE construct is recognized by the viral structural proteins expressed in a packaging cell line and packaged into infectious retroviral particles. Because the RNA transcript packaged in these particles does not contain the viral genes, it cannot replicate in the target cells that it infects.

The level of induction in cell populations infected with this vector depends on the efficiency of infection, the site of integration, and the titer of the virus. Viral supernatants with titers >10⁵ cfu/ml should be produced to achieve high-level induction.

Note: Clone in frame with the ATG at vector position 3329, within the *Sph* I site (if cloning downstream of it) of the vector MCS, so that translation of your gene of interest will not be affected.

Location of features:

- 5' MoMuSV LTR: 1-589
- Ψ⁺ (extended packaging signal): 659–1468
- Hygromycin resistance gene: 1510–2544
 - Start codon: 1510-1512; stop codon 2542-2544
- •TRE ([tetO]₇/P_{minCMV}): 2833–3276
- MCS: 3277-3354
- 3' MoMuLV LTR: 3390-3983
- Ampicillin resistance (β-lactamase) gene: 6139–5279
 Start codon: 6139–3137; stop codon 5277–5279

Propagation in *E. coli*:

- Suitable host strains: DH5 α , HB101, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (50 µg/ml) to E. coli hosts.
- E. coli replication origin: Col E1
- Copy number: low copy

References:

- 1. Miller, A. D. & Rosman, G. J. (1989) BioTechniques 7:980-990.
- 2. Tet Expression Systems and Cell Lines (July 1996) Clontchniques XI(3):2-5.
- 3. Gossen, M. & Bujard, H. (1992) Proc. Natl. Acad. Sci. USA 89:5547–5551.
- 4. RevTet-On & RevTet-Off Systems (April 1998) Clontechniques XIII(2):8-9.
- 5. Retroviruses (1997) CSHL Press.
- 6. Current Protocols in Molecular Biology (1996) Supplement 36, Section III

Notes:

The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

The viral supernatants produced by this retroviral vector could, depending on your cloned insert, contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant retrovirus. Appropriate NIH, regional, and institutional guidelines apply.

pRevTRE Vector Information

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. patents # 5,464,758 and #5,814,618, which are proprietary to TET Systems Holding GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwith-standing the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from IP Merchandisers in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems Holding GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems Holding GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to IP Merchandisers, Inc.

For license information, please contact:

Hans Peter Kneubuehl TET Systems Holding GmbH & Co. KG Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel +49 6221 588 04 00 Fax +49 6221 588 04 04 eMail: kneubuehl@tet-systems.de

or use our electronic licensing request form via http://www.tetsystems.com/main_inquiry.htm

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2007 Clontech Laboratories, Inc.